Oncology

A supplemental new drug application has been submitted to the FDA for ivosidenib tablets (Tibsovo) as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.

This activity is supported by educational grants from Seagen Inc., Daiichi Sankyo, and AstraZeneca.

Study findings illustrate the need for better communication between health care providers and patients experiencing concerns during the pandemic.

Directions in Oncology Pharmacy® talks to Gordon Vanscoy, PharmD, MBA, CACP, recently named a national Entrepreneur of the Year for 2020 by Ernst & Young.

As immunotherapies continue to show promise in more effectively combating several tumor types, many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly to tumors.

“Digital medicine and its regulation are constantly evolving, which is a great thing.”—Betsy Cernero, PharmD

Pharmacy Times® interviewed David Silverstein, JD, MS, a partner in Axinn’s Intellectual Property and FDA practice groups, on what may be coming to market in the rapidly growing cell therapy space, and the role pharmacists may play in this emerging landscape.

Addressing genomic differences and socioeconomic disparities is essential in order to address the higher incidences and mortality rates for prostate cancer among African American men.

Study findings suggest that enhanced cleaning and disinfecting policies are effective at reducing the spread of COVID-19.

This activity is supported by an educational grant from Incyte Corporation.

The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma.

A more sensitive test capable of detecting heart function issues early in cancer treatment may be beneficial in preventing heart failure.

This activity is supported by an independent medical education grant from AcelRx Pharmaceuticals, Inc.

In a live virtual symposium presented at the 2020 ASHP Midyear Clinical Meeting and Exhibition, Allison Baxley, PharmD, BCOP, and Laura Alwan, PharmD, BCOP, engaged pharmacists in learning about the role of biomarkers in cervical and endometrial cancers.

Often, patients with cancer face having to quit their jobs, apply for disability payments, and deplete their savings, which can lead to bankruptcy.

The FDA has approved the PD-L1 IHC 22C3 pharmDx assay, developed by Agilent Technologies Inc, for expanded use in patients with non–small cell lung cancer.

The time to treatment deterioration in pain in chest, dyspnea, and cough was found to be comparable between patients who received lorlatinib and patients who received crizotinib.

Pharmacy Times® interviewed J. David Robertson, PhD, director of University of Missouri Research Reactor, on a new collaboration with Advanced Accelerator Applications International to develop a targeted therapy for certain types of cancerous tumors.

Two expert speakers at the 2020 ASHP Midyear Clinical Meeting and Exhibition presented Immune Checkpoint Inhibitors: Resolving Dosing Confusion to Better Care for Patients With Cancer, a virtual symposium.

Statins have become a standard part of treatment for certain patients with cancer to prevent cardiotoxicity and promote antitumor activity.

The FDA has granted a fast track designation to the DNA-mediated interleukin-12 immunotherapy GEN-1 for use in the treatment of patients with advanced ovarian cancer.

This is the third approval for Libtayo, following approvals as the first immunotherapy for patients with advanced basal cell carcinoma and as the first systemic treatment for advanced cutaneous squamous cell carcinoma.

A deep learning model was found to support the identification of imaging biomarkers on screening mammograms, according to researchers at Massachusetts General Hospital.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

As a direct result of the global pandemic, the landscape for oncology health care professionals has changed.

Current cancer research focuses heavily on adjunct immunotherapy in combination with traditional chemotherapy.

A 5% weight loss over 2 years in patients with HER2-positive early breast cancer was associated with worse outcomes, according to new research that investigated the BMI data of these patients.

Presentation provides an overview of recent FDA approvals for therapies utilized in patients with various cancer types.

Two supplemental BLAs have been submitted to the FDA for enfortumab vedotin-ejfv to convert its accelerated approval into a regular one and to expand the current label to include patients with locally advanced or metastatic urothelial cancer.

The classes of approved cell and gene therapies are expected to expand rapidly in the next few years based on projections in the field.